SHENZEN, CHINA, Dec. 11, 2017 --
ZTE Corporation, a major international provider of telecommunications, enterprise and consumer technology solutions for the Mobile Internet, today announced that it has provided its experimental system, specifically the 5th Generation mobile communication system (5G) base stations and core network equipment, for the 4.5GHz band substantiative experiment of SoftBank, which obtained its experimental license on 20 November, 2017.
Both sides will start the substantiative experiment at experimental sites constructed at Shiba-Daimon area in Tokyo.
ZTE has established close relationships by cooperating with SoftBank to execute substantiative experiment of Massive MIMO, which is one of the important elemental technologies adopted for 5G starting 2015, and by supplying Massive MIMO equipment in SoftBank’s commercial networks since 2016.
SoftBank aims to use the substantiative experiment for its 5G commercial services which are due to start around 2020, and will execute further experiments for 5G introductions based on the know-how accumulated by both parties.
SoftBank has implemented new radio interface to be adopted for 5G and Massive MIMO, and has scheduled experiments with multiple terminals in densely built buildings such as central Tokyo. Meanwhile, SoftBank has planned experiments for actual use cases like enhanced mobile broadband communication and mobility verifications etc.
ZTE, a pioneer of 5G technologies, has driven 5G technology verifications and experiments targeting for commercial deployments together with global operators like SoftBank. Underpinned by its leadership in 5G technologies, the company is committed to helping carriers deploy the latest network innovations and smoothly evolve from 4.5G networks, supporting the ongoing digital transformation of operators globally.
About ZTE
ZTE is a provider of advanced telecommunications systems, mobile devices, and enterprise technology solutions to consumers, carriers, companies and public sector customers. As part of ZTE’s strategy, the company is committed to providing customers with integrated end-to-end innovations to deliver excellence and value as the telecommunications and information technology sectors converge. Listed in the stock exchanges of Hong Kong and Shenzhen (H share stock code: 0763.HK / A share stock code: 000063.SZ), ZTE’s products and services are sold to over 500 operators in more than 160 countries. ZTE commits 10 per cent of its annual revenue to research and development and has leadership roles in international standard-setting organizations. ZTE is committed to corporate social responsibility and is a member of the UN Global Compact. For more information, please visit www.zte.com.cn.
ZTE Margaret Ma +8675526775189 [email protected]


Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



